Our Mission: Cure Desmoid Tumors
The Desmoid Tumor Research Foundation (DTRF) empowers and unites everyone committed to finding answers for the desmoid tumor community. We aggressively fund desmoid tumor research, accelerate the development of improved therapies, drive collaborations among clinicians and researchers worldwide, and support patients and doctors through education. Our goal is to find a cure for each and every patient diagnosed with this rare disease.
EXPLORE THE RESEARCH WE’VE FUNDED AT PRESTIGIOUS INSTITUTIONS AROUND THE WORLD.
|Year||Principal Investigator||Award Title|
|Year2019||Principal InvestigatorAaron Weiss, DO and Fariba Navid, MD, Children’s Hospital Los Angeles||Award Title“Comprehensive genomic analysis of desmoid tumors in pediatric patients treated on ARST1921: a children’s oncology group study evaluating the safety, pharmacokinetic and efficacy of a γ-secretase inhibitor, Nirogacestat (PF-03084014).” Year 1 of 3||View Project|
|Year2019||Principal InvestigatorAaron Weiss, DO and Fariba Navid, MD, Children’s Hospital Los Angeles||Award Title“Patient reported outcomes (PROs) in pediatric patients with desmoid tumor treated on ARST1921: a children’s oncology group study evaluating the safety, pharmacokinetic and efficacy of a γ-secretase inhibitor, Nirogacestat (PF-03084014).” Year 1 of 1||View Project|
|Year2019||Principal InvestigatorPaul Huang, PhD, The Institute of Cancer Research, London, UK||Award Title“Characterising the desmoid tumour matrisome for biomarker and drug target discovery.” Year 1 of 1||View Project|
|Year2019||Principal InvestigatorJesse Boehm, PhD, Associate Director of the Cancer Program, Director of the Cancer Cell Line Factory, Principal Investigator in the Cancer Model Development Center, Institute Scientist, The Broad Institute of MIT and Harvard||Award Title“Using genome-scale CRISPR screening to create a desmoid tumor dependency map.” Year 1 of 3||View Project|
|Year2018||Principal InvestigatorKris Vleminckx, PhD, Ghent University, Belgium||Award Title“Identifying targets for therapy in a novel genetic Xenopus model for desmoid tumor formation.” Year 3 of 3||View Project|
|Year2018||Principal InvestigatorBenjamin Alman, MD, and Mushriq Al-Jazrawe, HBSc, PhD Candidate, The Hospital for Sick Children, Toronto, Ontario, Canada||Award Title“Single cell-derived clonal analysis of desmoid tumors to investigate tumor-stroma interactions.” Year 3 of 3.||View Project|
|Year2018||Principal InvestigatorPeter Hohenberger, MD, PhD, Medical Faculty, Mannheim, University of Heidelberg, Germany||Award Title“An evidence-based consensus on the treatment of desmoids/aggressive fibromatosis.” Year 1 of 1.||View Project|
|Year2018||Principal InvestigatorBenjamin Wilke, MD, and Steven Attia, DO, Mayo Clinic||Award Title“A pilot study of intralesional injection of triamcinolone acetonide for desmoid tumors.” Year 1 of 1.||View Project|
|Year2018||Principal InvestigatorO. Hans Iwenofu, MD, FCAP, and Michael Freitas, PhD, The Ohio State University||Award Title“Quantitative proteomics analysis of desmoid-type fibromatosis.” Year 1 of 1.||View Project|
|Year2018||Principal InvestigatorBenjamin Alman, MD, Duke University||Award Title“A genetically targeted mouse model of desmoid tumors.” Year 1 of 1.||View Project|
Clinicians & Researchers Newsletter
Receive monthly updates about treatment advances, grant applications, clinical trials, CME opportunities, and more.